SCHEMBL26837486

SCHEMBL26837486

CC(=O)N1CCC[C@H]1C(=O)NC(c1ccccc1)c1ccc(C2CC2)cn1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 1/20 0.46
▸ S1PR3 Q99500 2/20 0.46
▸ TACR1 P25103 7/20 0.45
▸ MAPK10 P53779 1/20 0.41
▸ CPA1 P15085 1/20 0.41
▸ CPA2 P48052 1/20 0.41
▸ CPA4 Q9UI42 1/20 0.41
▸ XIAP P98170 3/20 0.40
▸ BIRC3 Q13489 1/20 0.40
▸ BIRC2 Q13490 1/20 0.40
▸ BIRC8 Q96P09 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ S1PR1 P21453 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ DPP8 Q6V1X1 1/20 0.38
▸ DPP7 Q9UHL4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24666220 0.89 S1PR3 (0.47) CFDS1PR3TACR1BIRC2BIRC8
SCHEMBL24665904 0.87 CFD (0.47) CFDTACR1MAPK10CPA1CPA2
SCHEMBL29231340 0.87 CFD (0.47) CFDTACR1MAPK10CPA1CPA2
SCHEMBL29230910 0.83 S1PR3 (0.44) CFDS1PR3TACR1XIAPBIRC3
SCHEMBL30341348 0.83 S1PR3 (0.44) CFDS1PR3TACR1XIAPBIRC3
SCHEMBL24665658 0.83 S1PR3 (0.44) CFDS1PR3TACR1XIAPBIRC3
SCHEMBL27367691 0.83 S1PR3 (0.41) CFDS1PR3TACR1S1PR1DPP8
SCHEMBL26819615 0.83 TACR1 (0.42) CFDS1PR3TACR1DPP8DPP7
SCHEMBL24664655 0.82 S1PR3 (0.41) CFDS1PR3TACR1XIAPBIRC3
SCHEMBL29231197 0.82 S1PR3 (0.41) CFDS1PR3TACR1XIAPBIRC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL CFD 4871/4885S1PR3 3590/4885TACR1 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback